Novacyt S.A. ( (NVYTF) ) has released its Q2 earnings. Here is a breakdown of the information Novacyt S.A. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Novacyt S.A. is an international molecular diagnostics company specializing in genomic medicine, offering a wide range of molecular assays and instrumentation for sectors such as human health, animal health, and environmental applications. In its latest half-year financial report for 2025, Novacyt reported a slight decline in revenue to £9.8 million compared to the previous year, with a notable increase in demand for its reproductive health products, particularly in the Asia-Pacific region. The company also launched a new genomic research instrument, LightBench® Discover, and received EU accreditation for its Yourgene assays. Despite a reduced EBITDA loss of £4.1 million, Novacyt remains debt-free with a cash reserve of £23.7 million, reflecting its strategic focus on cost-saving measures and R&D investment. Looking ahead, Novacyt’s management is optimistic about achieving EBITDA profitability through organic growth, having resolved legacy issues and streamlined operations to focus on product development and market expansion.